Related Experiment Videos
Carboplatin-based chemotherapy for bladder cancer
1Department of Clinical Oncology, Royal Postgraduate Medical School, Hammersmith Hospital, London, U.K.
Cancer Treatment Reviews
|January 1, 1993
Summary
This study shows methotrexate/vinblastine/mitoxantrone/carboplatin chemotherapy offers hope for advanced urothelial cancer. Many patients experienced significant tumor reduction and improved survival, especially those with locally advanced disease.
Area of Science:
- Oncology
- Urothelial Carcinomas
- Chemotherapy
Background:
- Urothelial cancer prognosis is poor with conventional treatments, particularly for locally advanced stages.
- There is a need for effective systemic therapies to improve outcomes.
Purpose of the Study:
- To evaluate the efficacy and response rates of MVMJ (methotrexate/vinblastine/mitoxantrone/carboplatin) chemotherapy in patients with urothelial cancer.
- To assess treatment outcomes in both locally advanced and metastatic urothelial cancer cohorts.
Main Methods:
- A clinical trial involving 72 patients with urothelial cancer.
- Sixty-four evaluable patients received MVMJ chemotherapy.
- Data collection included response rates (complete response, partial response, stable disease), disease progression, and survival.
Main Results:
- Overall, 45% of patients (29/64) achieved a complete or partial response.
- Complete response rates were 32% (12/37) in locally advanced disease and 18% (5/27) in metastatic disease.
- Median survival was not reached for responding patients, with observed survival up to 1131+ days for locally advanced and 497 days for metastatic complete responders.
Conclusions:
- MVMJ chemotherapy demonstrates significant activity in urothelial cancer, including locally advanced and metastatic settings.
- The treatment offers a potential survival benefit for responding patients.
- Further investigation into MVMJ chemotherapy for urothelial cancer is warranted.